Cingulate Inc Secures $3M Grant for Anxiety Drug

The latest update is out from Cingulate Inc ( (CING) ).

On April 8, 2025, Cingulate Inc. entered into a Grant Agreement with a private foundation to receive a $3 million grant for the development of CTx-2103, a once-daily formulation of buspirone for anxiety treatment. This funding, distributed in three $1 million payments, will accelerate Cingulate’s pipeline and validate its PTR technology, potentially reducing reliance on benzodiazepines and addressing a significant market need in the $5.5 billion U.S. anxiety market.

Spark’s Take on CING Stock

According to Spark, TipRanks’ AI Analyst, CING is a Neutral.

Cingulate Inc.’s stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, including progress towards FDA approval for CTx-1301, provide a significant positive outlook. Technical indicators show neutral market momentum, but valuation remains a concern due to financial losses and lack of dividends.

To see Spark’s full report on CING stock, click here.

More about Cingulate Inc

Cingulate Inc. is a biopharmaceutical company based in Kansas City, utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to develop next-generation pharmaceutical products. The company focuses on improving treatment outcomes for conditions with burdensome daily dosing, initially targeting ADHD and expanding into anxiety disorders.

YTD Price Performance: -29.22%

Average Trading Volume: 106,363

Technical Sentiment Signal: Strong Buy

Current Market Cap: $14.09M

Learn more about CING stock on TipRanks’ Stock Analysis page.